SR 141716A

Name: SR 141716A
Brand: Tocris Bioscience
SKU: 0923
Rating: 5 (1 reviews)

Tocris Bioscience a Bio-Techne Brand

Catalog # 0923

Citations (18)

(1)

COA / SDS

Catalog #

Availability

Size / Price

Qty

Key Product Details

Description:	Selective CB₁ inverse agonist
Alternative Names:	Rimonabant hydrochloride
Chemical Name:	N-(Piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide hydrochloride
Purity:	≥99% (HPLC)
Molecular Weight:	500.25

View Full Technical Details for SR 141716A

Biological Activity for SR 141716A

SR 141716A is a potent and selective cannabinoid CB₁ receptor antagonist (K_i= 1.98 nM). Also acts as an inverse agonist reversing adenylyl cyclase inhibition by WIN 55,212-2 (Cat.No. 1038) (IC₅₀ = 48 nM). Displays no activity at CB₂ receptors. Reduces food intake and body weight in orally dosed non-obese Wistar rats. Also μ-opioid receptor antagonist (K_i = 652 nm)

Technical Data for SR 141716A

M. Wt	500.25
Formula	C₂₂H₂₁Cl₃N₄O.HCl
Storage	Desiccate at RT
Purity	≥99% (HPLC)
CAS Number	158681-13-1
PubChem ID	104849
InChi Key	REOYOKXLUFHOBV-UHFFFAOYSA-N
Smiles	O=C(NN4CCCCC4)C1=NN(C3=CC=C(Cl)C=C3Cl)C(C2=CC=C(Cl)C=C2)=C1C.Cl

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility for SR 141716A

	Solvent	Max Conc. mg/mL	Max Conc. mM
Solubility
Solubility	DMSO	50.02	100

Preparing Stock Solutions for SR 141716A

The following data is based on the product molecular weight 500.25.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.00 mL	10.00 mL	19.99 mL
5 mM	0.40 mL	2.00 mL	4.00 mL
10 mM	0.20 mL	1.00 mL	2.00 mL
50 mM	0.04 mL	0.20 mL	0.40 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt*

g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1 (C1)

Volume 1 (V1)

Concentration 2 (C2)

Volume 2 (V2)

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

References for SR 141716A

References are publications that support the biological activity of the product.

Seely AM-251 and rimon. act as direct antagonists at mu-opioid receptors: implications for opioid/cannabinoid interaction studies. Neuropharmacology 2012 PMID: 22771770
Janiak Blockade of cannabinoid CB₁ receptors improves renal function, metabolic profile, and increased survival of obese Zucker rats. Kidney Int. 2007 PMID: 17882151
Colombo Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. Life Sci. 1998 PMID: 9718088
Rinaldi-Carmona Biochemical and pharmacological characterisation of SR 141716A, the first potent and selective brain cannabinoid receptor antagonist. Life Sci. 1995 PMID: 7776817
Rinaldi-Carmona SR 141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 1994 PMID: 8070571

Citations for SR 141716A (18)

Showing 1 - 10 of 18 citations Showing All

Search Title:

Citations are publications that use Bio-Techne products. Selected citations for SR 141716A include:

Pedersen et al. (2021) A novel luminescence-based-β-arrestin recruitment assay for unmodified receptors J Biol Chem. 296:100503
PMID: 33684444
Jimenez-Blasco et al. (2020) Glucose metabolism links astroglial mitochondria to cannabinoid effects. Nature. 583:603
PMID: 32641832
Cecconi et al. (2019) Role of Major Endocannabinoid-Binding Receptors during Mouse Oocyte Maturation. Int J Mol Sci. 20
PMID: 31212770
Khan et al. (2018) Involvement of the CB₂ cannabinoid receptor in cell growth inhibition and G0/G1 cell cycle arrest via the cannabinoid agonist WIN 55,212-2 in renal cell carcinoma. BMC Cancer. 18:583
PMID: 29792186
Jiang et al. (2017) Antidepressant-like effects of fenofi. in mice via the hippocampal brain-derived neurotrophic factor signalling pathway. Br J Pharmacol. 174:177
PMID: 27861729
Klingerman et al. (2016) Acute Metabolic Effects of olanz. Depend on Dose and Injection Site. Dose Response. 13:1559325815618910
PMID: 26740814
Hayase (2016) Putative Epigenetic Involvement of the Endocannabinoid System in Anxiety- and Depression-Related Behaviors Caused by Nicotine as a Stressor. PLoS One. 11:e0158950
PMID: 27404492
Bruijnzeel et al. (2016) Behavioral Characterization of the Effects of Cannabis Smoke and Anandamide in Rats. PLoS One. 11:e0153327
PMID: 27065006
Tang and Alger (2015) Homer protein-metabotropic glutamate receptor binding regulates endocannabinoid signaling and affects hyperexcitability in a mouse model of fragile X syndrome. J Neurosci. 35:3938
PMID: 25740522
Mahmoud et al. (2015) (4-(Bis(4-fluorophenyl)methyl)piperazin-1-yl)(cyclohexyl)methanone hydrochloride (LDK1229): a new cannabinoid CB1 receptor inverse agonist from the class of benzhydryl piperazine analogs. Mol Pharmacol. 87:197
PMID: 25411367
Marcu et al. (2013) Novel insights into CB1 cannabinoid receptor signaling: a key interaction identified between the extracellular-3 loop and transmembrane helix 2. J Pharmacol Exp Ther. 345:189
PMID: 23426954
Sumislawski et al. (2011) Reversible gating of endocannabinoid plasticity in the amygdala by chronic stress: a potential role for monoacylglycerol lipase inhibition in the prevention of stress-induced behavioral adaptation. Neuropsychopharmacology. 36:2750
PMID: 21849983
Kapur et al. (2008) Mapping the structural requirements in the CB1 cannabinoid receptor transmembrane helix II for signal transduction. J Pharmacol Exp Ther. 325:341
PMID: 18174385
Graham et al. (2006) Induction of Krox-24 by endogenous cannabinoid type 1 receptors in Neuro2A cells is mediated by the MEK-ERK MAPK pathway and is suppressed by the phosphatidylinositol 3-kinase pathway. Br J Pharmacol. 281:29085
PMID: 16864584
Kettunen et al. (2005) Neuromodulation via conditional release of endocannabinoids in the spinal locomotor network. Neuron. 45:95
PMID: 15629705
Stanford et al. (2001) Identification of two distinct vasodilator pathways activated by ATP in the mesenteric bed of the rat. Br J Pharmacol. 133:825
PMID: 11454655
Martin et al. (2000) Effects of cannabinoid receptor agonists on neuronally-evoked contractions of urinary bladder tissues isolated from rat, mouse, pig, dog, monkey and human. Front Mol Neurosci. 129:1707
PMID: 10780977
MacLennan et al. (1998) Evidence for inverse agonism of SR141716A at human recombinant cannabinoid CB1 and CB2 receptors. Br J Pharmacol. 124:619
PMID: 9690851

There are no citations that match your criteria.

Showing 1 - 10 of 18 citations Showing All

Customer Reviews for SR 141716A (1)

5 out of 5

1 customer rating

5 stars

100%

4 stars

3 stars

2 stars

1 star

Customer Images

Showing 1 - 1 of 1 review Showing All

Filter By:

Highly recommend.

Name: Anonymous

Species: Mouse

Assay Type: Ex Vivo

Cell Line/Tissue: Bed nucleus of the stria terminalis

SR 141716A was solubilized in DMSO and bath applied at a 5 micromolar concentration. It effectively blocked CB1-receptor-dependent long term depression of evoked excitatory postsynaptic current in the bed nucleus of the stria terminalis.

PMID: 27956747

There are no reviews that match your criteria.

Showing 1 - 1 of 1 review Showing All

Product Documents for SR 141716A

COA

Certificate of Analysis

To download a Certificate of Analysis, please select a batch below.